Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
ALDACTONE vs TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Triamterene inhibits sodium reabsorption in the distal renal tubules by blocking epithelial sodium channels, reducing potassium excretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter, leading to increased diuresis and natriuresis.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
Adults: 1 capsule (triamterene 37.5 mg / hydrochlorothiazide 25 mg) orally once daily or twice daily; maximum triamterene 150 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Triamterene: 1.5-2.5 hours (terminal), prolonged in hepatic impairment; Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Triamterene: renal 21-50% (unchanged) and 40-54% (metabolites); Hydrochlorothiazide: renal >95% unchanged.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic